Emerging biotechnologies: full report - Nuffield Council on Bioethics
Emerging biotechnologies: full report - Nuffield Council on Bioethics
Emerging biotechnologies: full report - Nuffield Council on Bioethics
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
E m e r g i n g b i o t e c h n o l o g i e s<br />
public engagement 5.52–5.54, 5.53–5.55<br />
range of competence 5.31<br />
range of expertise 5.31<br />
<str<strong>on</strong>g>report</str<strong>on</strong>g>ing of deliberati<strong>on</strong>s 5.46, 10.8<br />
virtue of candour 4.50–4.51<br />
vs n<strong>on</strong>-experts 5.30<br />
see also researchers<br />
secti<strong>on</strong>al interests 4.38, 5.63<br />
influences over the media 5.14–5.16, 5.19<br />
of private sector scientists 9.7<br />
transcending 5.27<br />
semic<strong>on</strong>ductors 3.23, 6.30–6.31<br />
serendipity 3.7<br />
shareholders' interests 9.5, 9.7, 9.10<br />
short interfering RNAs (siRNAs) 2.13<br />
silkworms, transgenic 2.10, 2.28<br />
single molecule biophysics 2.25<br />
slippery slope argument 4.14, 6.44<br />
Smith, Adam 9.2<br />
social choices 5.59–5.60<br />
social c<strong>on</strong>sequences, uncertainties 3.8<br />
social c<strong>on</strong>tract theory 4.17<br />
social networking 5.12<br />
social objectives 7.48, 7.57, 10.15<br />
social relati<strong>on</strong>s, technological determinism 4.16<br />
social scientists 5.31, 6.61<br />
social shaping, emerging <str<strong>on</strong>g>biotechnologies</str<strong>on</strong>g><br />
9.65–9.66<br />
social value 1.34<br />
commercialisati<strong>on</strong> and 9.52–9.54, 9.71–<br />
9.72, 10.21<br />
incentives reflecting 9.55–9.70<br />
societal attitudes, accounting for 8.12–8.13<br />
societal issues, addressing 6.36–6.37, 7.53–<br />
7.55, 10.16<br />
sociotechnical imaginaries 2.34–2.35<br />
solidarity 4.30, 4.56<br />
Spinks Report (1980) 7.4<br />
spin-outs (spin-offs) 6.5, 6.13<br />
influences <strong>on</strong> research 6.22<br />
promoti<strong>on</strong> of 6.39<br />
research and profit-seeking 9.10–9.12<br />
successful 7.4<br />
start-ups 6.5, 6.22<br />
steam engine 3.23, Box 3.3<br />
stem cell research 1.22, 2.5–2.6, 2.28, 2.37,<br />
8.22<br />
strategic advisory bodies, UK 7.6–7.9<br />
Strategy for UK life sciences (BIS) 7.15–7.16<br />
A strategy for UK regenerative medicine (MRC)<br />
7.16<br />
submerged <str<strong>on</strong>g>biotechnologies</str<strong>on</strong>g> 2.42<br />
surrogate endpoints 9.51<br />
surveillance 8.28, 8.39<br />
sustainability 4.31–4.32, 4.56<br />
synthetic biology 2.2, 2.18–2.23, 6.19<br />
bricolage approach 9.35<br />
ec<strong>on</strong>omic exploitability 7.40<br />
ec<strong>on</strong>omic growth agenda 7.13–7.15<br />
exclusi<strong>on</strong> of DIYBio groups 6.56<br />
interdisciplinary nature 6.19, 6.61<br />
leadership council 6.35, 7.13<br />
parts-based (BioBricks®) 1.14, 2.19, 9.46<br />
potential applicati<strong>on</strong>s 7.15<br />
regulatory aspects 8.13<br />
roadmapping 6.32–6.35, 7.13, 7.54<br />
visi<strong>on</strong>s 1.4, 2.36–2.38<br />
vs genetic engineering 2.18<br />
systemic risks 3.4<br />
systems biology 6.19<br />
tax incentives 9.52<br />
technological change 3.22–3.25<br />
technological determinism 4.15–4.16<br />
technological lock-in 1.8, 1.24–1.26, 1.28, 3.24<br />
technological momentum 1.24<br />
technological paradigms 1.31, 3.24<br />
technological pathways see pathways,<br />
technological<br />
technology c<strong>on</strong>trol dilemma, Collingridge's<br />
1.27–1.29, Box 1.2<br />
Technology Strategy Board (TSB)<br />
data provisi<strong>on</strong> 6.5<br />
ec<strong>on</strong>omic growth agenda 7.12, 7.15–7.16<br />
funding of research 6.9, 6.10<br />
influence of industry over 7.52<br />
innovati<strong>on</strong> platform 4.32<br />
membership 7.52<br />
technoscientific imaginary 2.34<br />
technostructure 9.6<br />
televisi<strong>on</strong> 5.11<br />
terraforming 2.38<br />
terrorism Box 3.1, 8.10<br />
therapeutic cl<strong>on</strong>ing 2.6<br />
therapeutic targets<br />
crowdsourcing 9.50, Box 9.3<br />
validated 9.49–9.50<br />
third industrial revoluti<strong>on</strong> 2.36<br />
third stream funding 6.38<br />
tick box ethics 4.39<br />
timescales of emergence 2.28, 2.43, 4.50<br />
tomatoes, genetically modified (GM) 2.8<br />
trade associati<strong>on</strong>s 6.28<br />
trade secrets 9.18, 9.21<br />
trajectories, technological see pathways,<br />
technological<br />
transformative potential 3.1, 3.22–3.25, 3.37<br />
guiding research policy 7.42–7.43<br />
public ethics approach 4.15, 4.18–4.19<br />
transgenic animals 2.10–2.11, 3.19<br />
transgenic plants 9.38–9.39, 9.69<br />
transhumanism 2.34, 3.19<br />
transplantati<strong>on</strong> 2.6, 2.11<br />
trastuzumab 2.12<br />
Treasury, the 6.24, 7.11, 7.56, 10.18<br />
tunnelling problem 2.33, 2.47<br />
type 1 emerging <str<strong>on</strong>g>biotechnologies</str<strong>on</strong>g> 9.34–9.36<br />
I N D E X<br />
207